|
1
|
Barakat RR, Grisby PW and Sabbatini:
Corpus: epithelial tumor. Principles and Practice of Gynecologic
Oncology. Hoskin WJ, Perez CA and Young RC: 2nd edition. Lippincott
Williams & Wilkins; Philadelphia, PA: pp. 919–959. 2007
|
|
2
|
Fader AN, Arriba LN, Frasure HE and von
Gruenigen VE: Endometrial cancer and obesity: Epidemiology,
biomarkers, prevention and survivorship. Gynecol Oncol.
114:121–127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
von Gruenigen VE, Gil KM, Frasure HE,
Jenison EL and Hopkins MP: The impact of obesity and age on quality
of life in gynecologic surgery. Am J Obstet Gynecol. 193:1369–1375.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giovannucci E, Harlan DM, Archer MC,
Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and
Yee D: Diabetes and cancer: A consensus report. Diabetes Care.
33:1674–1685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chia VM, Newcomb PA, Trentham-Dietz A and
Hampton JM: Obesity, diabetes, and other factors in relation to
survival after endometrial cancer diagnosis. Int J Gynecol Cancer.
17:441–446. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calle EE, Rodriguez C, Walker-Thurmond K
and Thun MJ: Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med.
348:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pollak M: Metformin and other biguanides
in oncology: Advancing the research agenda. Cancer Prev Res
(Phila). 3:1060–1065. 2010. View Article : Google Scholar
|
|
8
|
Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y
and Liao QP: Metformin promotes progesterone receptor expression
via inhibition of mammalian target of rapamycin (mTOR) in
endometrial cancer cells. J Steroid Biochem Mol Biol. 126:113–120.
2011. View Article : Google Scholar
|
|
9
|
Emami Riedmaier A, Fisel P, Nies AT,
Schaeffeler E and Schwab M: Metformin and cancer: From the old
medicine cabinet to pharmacological pitfalls and prospects. Trends
Pharmacol Sci. 34:126–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smith U and Gale EA: Does diabetes therapy
influence the risk of cancer? Diabetologia. 52:1699–1708. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gallagher EJ and LeRoith D: The
proliferating role of insulin and insulin-like growth factors in
cancer. Trends Endocrinol Metab. 21:610–618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amori RE, Lau J and Pittas AG: Efficacy
and safety of incretin therapy in type 2 diabetes: Systematic
review and meta-analysis. JAMA. 298:194–206. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bastien-Dionne PO, Valenti L, Kon N, Gu W
and Buteau J: Glucagon-like peptide 1 inhibits the sirtuin
deacetylase SirT1 to stimulate pancreatic β-cell mass expansion.
Diabetes. 60:3217–3222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bose AK, Mocanu MM, Carr RD, Brand CL and
Yellon DM: Glucagon-like peptide 1 can directly protect the heart
against ischemia/reperfusion injury. Diabetes. 54:146–151. 2005.
View Article : Google Scholar
|
|
15
|
Kimura R, Okouchi M, Fujioka H, Ichiyanagi
A, Ryuge F, Mizuno T, Imaeda K, Okayama N, Kamiya Y, Asai K, et al:
Glucagon-like peptide-1 (GLP-1) protects against
methylglyoxal-induced PC12 cell apoptosis through the
PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience.
162:1212–1219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elashoff M, Matveyenko AV, Gier B,
Elashoff R and Butler PC: Pancreatitis, pancreatic, and thyroid
cancer with glucagon-like peptide-1-based therapies.
Gastroenterology. 141:150–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ligumsky H, Wolf I, Israeli S, Haimsohn M,
Ferber S, Karasik A, Kaufman B and Rubinek T: The peptide-hormone
glucagon-like peptide-1 activates cAMP and inhibits growth of
breast cancer cells. Breast Cancer Res Treat. 132:449–461. 2012.
View Article : Google Scholar
|
|
18
|
Koehler JA, Kain T and Drucker DJ:
Glucagon-like peptide-1 receptor activation inhibits growth and
augments apoptosis in murine CT26 colon cancer cells.
Endocrinology. 152:3362–3372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Samson SL and Bajaj M: Direct actions of
GLP-1 analogues on AMP-activated protein kinase activity are
distinct from cyclic AMP accumulation. J Hepatol. 58:634–635. 2013.
View Article : Google Scholar
|
|
20
|
Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H,
Chen Z, Zeng K and Weng J: SIRT1 mediates the effect of GLP-1
receptor agonist exenatide on ameliorating hepatic steatosis.
Diabetes. 63:3637–3646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang BB, Zhou G and Li C: AMPK: An
emerging drug target for diabetes and the metabolic syndrome. Cell
Metab. 9:407–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen BD, Zhao WC, Jia QA, Zhou WY, Bu Y,
Wang ZZ, Wang F, Wu WJ and Wang Q: Effect of the GLP-1 analog
exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell
line and mouse model. Int J Mol Sci. 14:24293–24304. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J,
Liu Y, Yang J, Hong T, Yang J, et al: Activation of glucagon-like
peptide-1 receptor inhibits tumourigenicity and metastasis of human
pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab.
16:850–860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Honors MA and Kinzig KP: Chronic exendin-4
treatment prevents the development of cancer cachexia symptoms in
male rats bearing the Yoshida sarcoma. Horm Cancer. 5:33–41. 2014.
View Article : Google Scholar :
|
|
25
|
Nomiyama T, Kawanami T, Irie S, Hamaguchi
Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga
H, et al: Exendin-4, a GLP-1 receptor agonist, attenuates prostate
cancer growth. Diabetes. 63:3891–3905. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Samani AA, Chevet E, Fallavollita L,
Galipeau J and Brodt P: Loss of tumorigenicity and metastatic
potential in carcinoma cells expressing the extracellular domain of
the type 1 insulin-like growth factor receptor. Cancer Res.
64:3380–3385. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Augustin LS, Dal Maso L, Franceschi S,
Talamini R, Polesel J, Kendall CW, Jenkins DJ and Vidgen E:
Association between components of the insulin-like growth factor
system and endometrial cancer risk. Oncology. 67:54–59. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirano S, Ito N, Takahashi S and Tamaya T:
Clinical implications of insulin-like growth factors through the
presence of their binding proteins and receptors expressed in
gynecological cancers. Eur J Gynaecol Oncol. 25:187–191.
2004.PubMed/NCBI
|
|
29
|
Pavelić J, Radaković B and Pavelić K:
Insulin-like growth factor 2 and its receptors (IGF 1R and IGF
2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol
Oncol. 105:727–735. 2007. View Article : Google Scholar
|
|
30
|
Shu S, Li X, Yang Y, Zhang Y, Li T, Liang
C and Wan J: Inhibitory effect of siRNA targeting IGF-1R on
endometrial carcinoma. Int Immunopharmacol. 11:244–249. 2011.
View Article : Google Scholar
|
|
31
|
Navarro M and Baserga R: Limited
redundancy of survival signals from the type 1 insulin-like growth
factor receptor. Endocrinology. 142:1073–1081. 2001.PubMed/NCBI
|
|
32
|
Schmelzle T and Hall MN: TOR, a central
controller of cell growth. Cell. 103:253–262. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mita MM, Mita A and Rowinsky EK: Mammalian
target of rapamycin: A new molecular target for breast cancer. Clin
Breast Cancer. 4:126–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feng Z, Zhang H, Levine AJ and Jin S: The
coordinate regulation of the p53 and mTOR pathways in cells. Proc
Natl Acad Sci USA. 102:8204–8209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hardie DG: AMPK: A key regulator of energy
balance in the single cell and the whole organism. Int J Obes.
32(Suppl 4): S7–S12. 2008. View Article : Google Scholar
|
|
37
|
Kahn BB, Alquier T, Carling D and Hardie
DG: AMP-activated protein kinase: Ancient energy gauge provides
clues to modern understanding of metabolism. Cell Metab. 1:15–25.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Inoki K, Zhu T and Guan KL: TSC2 mediates
cellular energy response to control cell growth and survival. Cell.
115:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu WW, Guan MP, Zheng ZJ, Gao F, Zeng YM,
Qin Y and Xue YM: Exendin-4 alleviates high glucose-induced rat
mesangial cell dysfunction through the AMPK pathway. Cell Physiol
Biochem. 33:423–432. 2014. View Article : Google Scholar : PubMed/NCBI
|
